USA David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health – concerns were behind the creation of the Marijuana Tax Act of 1937 and continue to persist to this day. With all this history, why…
Opinion Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics supply chain is standardized, transparent and dynamic, helping save the US healthcare system trillions of dollars. Savings have totaled…
USA Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be conducted in order to ensure the safety of rare disease patients – many of them children – who are using CBD products for their…
Canada Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new national ‘pharmacare’ program being proposed to remedy this situation, Pamela Fralick of Innovative Medicines Canada outlines the strengths and weaknesses of the proposal on the table and…
Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co. Now that we have all this data,…
USA Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will see AI bring to pharma companies and patients in the short and long term, as well as use cases for the technology.…
USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours. An American president determined to seal a trade deal. A newly elected Democratic majority with…
Opinion What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office of global management consultants Korn Ferry explain what they look for when hiring Mexico GMs, and outline some of the…
Opinion Meghann Chilcott, chief technology/marketing officer at Benzer Pharmacy provides insights for expanding point-of-care (POC) testing services in the US retail environment, and opportunities for improving patient outcomes and customer satisfaction in the process. POC testing makes it possible for patients to receive the treatment or the advice they need…
Mexico Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three key reasons why fighting corrupt practices is so important. The pharmaceutical industry must act according to value-based codes, building…
Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes. Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…
Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…
See our Cookie Privacy Policy Here